ArticleBMC urology2025
Outcomes of robotic prostatectomy with lymph node removal and early hormone therapy for locally advanced prostate cancer (pT3-4N0-1M0).
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTo investigate the efficacy and safety of robot-assisted radical prostatectomy (RARP) combined with extended pelvic lymph node dissection (ePLND) and immediate androgen deprivation therapy (ADT) for patients with locally advanced or lymph node metastatic prostate cancer (pT3-4N0-1M0).
methodsWe retrospectively analyzed clinical data from 40 patients with pT3-4N0-1M0 prostate cancer treated between April 2021 and April 2024. All patients had preoperative PSA > 20 ng/mL and received RARP + ePLND followed by immediate ADT. Postoperative follow-up ranged from 12 to 48 months, with records of surgical parameters, complications, urinary continence recovery, and biochemical recurrence.
resultsOperative time (207.4 ± 70.7 min), intraoperative blood loss (111.7 ± 127.8 mL), positive surgical margin rate (17.5%), and overall complication rate (10.0%) were all within acceptable ranges. Median postoperative hospitalization and catheter indwelling times were 7 and 22 days, respectively. Urinary continence recovery rates at 1, 3, 6, and 12 months were 62.5%, 85.0%, 90.0%, and 95.0%. During follow-up, one patient with positive margins (R1) and positive lymph nodes (N1) experienced biochemical recurrence at 3 years postoperatively, while one R1 but node-negative (N0) patient recurred at 4 years.
conclusionsRARP + ePLND combined with immediate ADT is safe and feasible for treating locally advanced or lymph node metastatic prostate cancer (pT3-4N0-1M0), providing patients with favorable functional recovery and oncological outcomes.
trial registrationNot applicable. (This study is a retrospective analysis and was not registered in a clinical trials registry.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.